@article{2a2295a572324daba9acdba504129b1e,
title = "Neurodegeneration With Brain Iron Accumulation (NBIA) Syndromes Presenting With Late-Onset Craniocervical Dystonia: An Illustrative Case Series",
abstract = "View Supplementary Video. Neurodegeneration with brain iron accumulation (NBIA) mostly has its disease onset in childhood, adolescence, or early adulthood and usually presents with predominant bulbar and axial dystonia along with signs such as spasticity, indicating an involvement of additional neurological systems. Because of their early onset and presentation with a combination of dystonia plus other neurological symptoms, they are usually not considered as differential diagnosis for late-onset isolated (idiopathic) craniocervical dystonia. In this case series, we present 4 genetically proven cases of NBIA (including neuroferritinopathy, pantothenate-kinase-associated neurodegeneration, and aceruloplasminemia) with late disease onset, which resembled isolated adult-onset craniocervical dystonia at disease onset. We also want to highlight the importance of taking NBIA into consideration when dealing with putatively isolated late-onset dystonias and of picking up unusual signs at later stages of the disease.",
keywords = "NBIA, craniocervical dystonia, isolated dystonia",
author = "Florian Brugger and Georg K{\"a}gi and Massimo Pandolfo and Mencacci, {Niccol{\`o} E.} and Amit Batla and Sarah Wiethoff and Bhatia, {Kailash P.}",
note = "Funding Information: Ethical Compliance Statement: We confirm that we have read the journal{\textquoteright}s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflicts of Interest: The authors report no sources of funding and no conflicts of interest. Financial disclosures for previous 12 months: F.B. received a travel grant from the International Parkinson and Movement Disorder Society and holds a research grant from Merz pharma Switzerland and the Swiss Neurological Society. G.K. is supported by grants from the Swiss Parkinson{\textquoteright}s Disease Association, the Halley Stuart Trust, and the Schweizerischen Herzstiftung. M.P. is supported by grants from the Belgian National Scientific Research Funds (FNRS), the Friedreich Ataxia Research Alliance, and BioMarin Pharma. He is a member of the scientific advisory board of Voyager Therapeutics and BioBlast and is a consultant for BioMarin. N.E.M. is supported by a Medical Research Council (MRC)/Wellcome Trust grant. S.W. is supported by the Brain Research Trust. K.P.B. holds research grants from the Gossweiler foundation, National Institute for Health Research Research for Patient Benefit, an MRC Wellcome Strategic grant (ref. no.: WT089698), and Parkinson{\textquoteright}s Disease UK (ref. no.: G-1009); has received honoraria/financial support to speak/attend meetings from GlaxoSmithKline, Boehringer Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva Lundbeck, and Orion pharmaceutical companies; and receives royalties from Oxford University Press and a stipend for Movement Disorders Clinical Practice editorship. Funding Information: Ethical Compliance Statement: We confirm that we have read the journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflicts of Interest: The authors report no sources of funding and no conflicts of interest. Financial disclosures for previous 12?months: F.B. received a travel grant from the International Parkinson and Movement Disorder Society and holds a research grant from Merz pharma Switzerland and the Swiss Neurological Society. G.K. is supported by grants from the Swiss Parkinson's Disease Association, the Halley Stuart Trust, and the Schweizerischen Herzstiftung. M.P. is supported by grants from the Belgian National Scientific Research Funds (FNRS), the Friedreich Ataxia Research Alliance, and BioMarin Pharma. He is a member of the scientific advisory board of Voyager Therapeutics and BioBlast and is a consultant for BioMarin.?N.E.M. is supported by a Medical Research Council (MRC)/Wellcome Trust grant. S.W. is supported by the Brain Research Trust. K.P.B. holds research grants from the Gossweiler foundation, National Institute for Health Research Research for Patient Benefit, an MRC Wellcome Strategic grant (ref. no.: WT089698), and Parkinson's Disease UK (ref. no.: G-1009); has received honoraria/financial support to speak/attend meetings from GlaxoSmithKline, Boehringer Ingelheim, Ipsen, Merz, Sun Pharma, Allergan, Teva Lundbeck, and Orion pharmaceutical companies; and receives royalties from Oxford University Press and a stipend for Movement Disorders Clinical Practice editorship. Publisher Copyright: {\textcopyright} 2016 International Parkinson and Movement Disorder Society",
year = "2017",
month = mar,
day = "1",
doi = "10.1002/mdc3.12393",
language = "English (US)",
volume = "4",
pages = "254--257",
journal = "Movement Disorders Clinical Practice",
issn = "2330-1619",
publisher = "John Wiley and Sons Ltd",
number = "2",
}